NCT07052695 2025-12-15Mosunetuzumab for CLL MRD ClearanceDana-Farber Cancer InstitutePhase 1/2 Recruiting40 enrolled
NCT02569476 2024-10-26BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid MalignanciesBeiGenePhase 1 Completed119 enrolled 34 charts
NCT02795182 2022-07-01Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell MalignanciesBeiGenePhase 1 Completed75 enrolled 17 charts